Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 10/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.40 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060855 | 0.83 | OPRD1 (0.45) | FAAHSLC6A7ALDH1A1NPC1RAB9A | |
| SCHEMBL3059313 | 0.83 | ABL1 (0.47) | MGLLSLC6A7ALDH1A1 | |
| SCHEMBL3064319 | 0.82 | FAAH (0.51) | FAAHRAB9A | |
| SCHEMBL3045491 | 0.81 | SLC6A7 (0.44) | MGLLFAAHSLC6A7ALDH1A1 | |
| SCHEMBL3068834 | 0.79 | MEN1 (0.41) | MGLLFAAHSLC6A7 | |
| SCHEMBL3044774 | 0.78 | MGLL (0.44) | MGLLFAAHSLC6A7ALDH1A1NPC1 | |
| SCHEMBL3055766 | 0.77 | ALDH1A1 (0.57) | MGLLALDH1A1NPC1RAB9A | |
| SCHEMBL3063959 | 0.76 | GRM5 (0.43) | MGLLSLC6A7ALDH1A1 | |
| SCHEMBL3067188 | 0.76 | MGLL (0.53) | MGLLHDAC4SLC6A7NPC1RAB9A | |
| SCHEMBL3068161 | 0.76 | RAB9A (0.38) | MGLLALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | MGLL 3668/4885HDAC4 527/4885FAAH 2797/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | MGLL 3668/4885HDAC4 527/4885FAAH 2797/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | MGLL 3668/4885HDAC4 527/4885FAAH 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.